DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Olmutinib
Olmutinib
YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small- Cell Lung Cancer
EGFR Mutant-Specific Inhibitor, in T790M+ NSCLC: #378 Efficacy and Safety at the RP2D
Structural Insights Into Characterizing Binding Sites in EGFR Kinase Mutants
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Osimertinib in EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer Ferdinandos Skoulidis and Vassiliki A
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors And
B1218-5,25 Olmutinib
Dabrafenib in Patients with BRAF-Mutated Non-Small Cell Lung Cancer
Investigation of the Metabolic Stability of Olmutinib by Validated LC-MS/MS: Quantification in Human Cite This: RSC Adv.,2018,8,40387 Plasma
Patient-Derived Cells to Guide Targeted Therapy for Advanced
Olmutinib Induced Lichen Planus Like Eruption Pissn 1013-9087ㆍeissn 2005-3894 Ann Dermatol Vol
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
3D in Vitro Models of Tumors Expressing EGFR Family Receptors: A
Update on Recent Preclinical and Clinical Studies of T790M Mutant
Epidermal Growth Factor Receptor; Erbb-1; HER1
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations
Distinct Characteristics and Clinical Outcomes to Predict the Emergence
Top View
A UHPLC–MS/MS Method for the Quantitation of Olmutinib in Rat Plasma
ATC/DDD Classification (Final)
Olmutinib (HM61713) Reversed Multidrug Resistance by Inhibiting the Activity of ATP- Binding Cassette Subfamily G Member 2 in Vitro and in Vivo
Lessons Learned from Ctdna NGS in 25,000 Advanced Cancer Patients in Clinical Practice
Clinical Development of Targeted and Immune Based Anti-Cancer Therapies N
Repurposing Drugs for COVID-19 Based on Transcriptional Response of Host Cells to SARS-Cov-2
Crystal Form of Olmutinib
Overcoming Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer
A Comparison Between First-, Second- and Third-Generation Epidermal
Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in T790M-Positive Non-Small Cell Lung Cancer: Review on Emerged Mechanisms of Resistance
Changelog (In Alphabetical Order of the Value Set) Value Set Code Description Change
W J C O Clinical Oncology
Olmutinib in T790M‐Positive Non–Small Cell Lung Cancer After Failure
Osimertinib in Advanced EGFR T790M-Positive Non-Small-Cell Lung Cancer: the Clinical Impact of AURA3
Third Generation EGFR Tkis
Emerging Targeted Therapies for the Treatment of Non-Small Cell Lung Cancer
Management of Acquired Resistance to EGFR TKI–Targeted Therapy in Advanced Non-Small Cell Lung Cancer Shang-Gin Wu and Jin-Yuan Shih*
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas Susan E
Tyrosine Kinase Receptors in Oncology